Newgenivf Group Limited (NIVF) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2023 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Newgenivf Group Limited  (NASDAQ: NIVF)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare


Newgenivf Group Limited's ROI from its fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Newgenivf Group Limited's ROI in the fourth quarter of 2025?
Newgenivf Group Limited achieved a return on average invested assets (ROI) of 32.87 % in its fourth quarter of 2025, which is below Newgenivf Group Limited's average return on investment, which stands at 171.81%.

ROI has improved compared to 0.47% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 42 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from to 166.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Investment Change TTM 1530.32 % 3009.45 % - - -
Y / Y Net Income Change TTM 8873.35 % - - - -
Investment (TTM) in Millions 30 29 29 29 4
Return On Investment (TTM) 32.87 % 0.47 % 0.66 % 1.18 % 5.97 %
NIVF's Overall Ranking # 166 # # # #
Seq. Investment Change TTM 27.81 % 40.21 % 80.19 % 404.88 % 143.78 %
Seq. Net Income Change TTM 8873.35 % 0 % 0 % 0 % -
Net Income (TTM) in Millions 10 0 0 0 0

NIVF Company Profile >> Back to NIVF Roi Comparisons >> See Annual NIVF Return On Investment



Return On Investment NIVF's Ranking
Within: No.
Industry # 1
Sector # 43
Overall # 166

Return On Investment Statistics
High Average Low
310.57 %
171.81 %
33.05 %
(Dec 31 2023)   (Dec 31 2025)







Financial Statements
Newgenivf Group Limited's IV. Quarter Investments $ 30 Millions NIVF's Balance sheet
Newgenivf Group Limited's IV. Quarter Income $ 10 Millions Quarterly NIVF's Income Statement
NIVF's Income by Division See NIVF's Income by Division


NIVF Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023

Total Investments in Millions 30 4 3 0 0
Y / Y Investment Growth 596.67 % 50.23 % - - -
Net Income in Millions 10 0 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment 32.34 % -10.98 % 3.77 % - -


Annual Roi Comment
In the fiscal year 2025 ROI improved to 32.34 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Healthcare Facilities Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NIVF's Roi Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NIVF's Competitors
Subscribers only: Roi for Newgenivf Group Limited's Suppliers
Subscribers only: Return On Investment for NIVF's Customers

Other Ratios
NIVF's Roa NIVF's Inventory Turnover Ratio NIVF's Growth Rates NIVF's Dividend Statistics
NIVF's Profitability Ratios NIVF's Asset Turnover Ratio NIVF's Dividend Growth
NIVF's Roe NIVF's Valuation Ratios NIVF's Financial Strength Ratios NIVF's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Biocryst Pharmaceuticals Inc   88.36 %
Advanced Biomed Inc.  84.64 %
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %

Date modified: 2026-09-02T16:46:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.